Page last updated: 2024-12-06

2,4-diaminopyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-diaminopyridine is a synthetic compound that acts as a potassium channel opener. It is structurally similar to the neurotransmitter adenosine and has been shown to have a variety of pharmacological effects, including the ability to improve cognitive function and reduce seizures. 2,4-diaminopyridine is also being investigated as a potential treatment for myasthenia gravis, a rare autoimmune disease that causes muscle weakness. 2,4-diaminopyridine is studied because of its potential to improve the symptoms of a variety of neurological disorders. It is a promising therapeutic target for a number of conditions, including epilepsy, stroke, and Alzheimer's disease.'

4-amino-2-iminopyridine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68036
CHEMBL ID338573
CHEBI ID51599
SCHEMBL ID43935
MeSH IDM0087673

Synonyms (35)

Synonym
461-88-1
CHEBI:51599 ,
2,4-pyridinediamine
pyridine, 2,4-diamino-
brn 0108514
2,4-diaminopyridine
pyridine-2,4-diamine
AC-907/34116042
CHEMBL338573
A7216
AKOS009171727
96832ti6en ,
5-22-11-00249 (beilstein handbook reference)
unii-96832ti6en
FT-0649437
AM20051206
SCHEMBL43935
2,4-diamino-pyridine
IFFLKGMDBKQMAH-UHFFFAOYSA-N
W-202818
pyridine-2,4-diyldiamine
F0001-0828
DTXSID30196723
CS-W008887
mfcd00234953
4-amino-2-iminopyridine
DS-11061
Q27122671
YSZC556
BCP27021
SB75573
EN300-110009
pyridine-2 pound not4-diamine
SY013827
Z851810344
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diaminopyridineCompounds containing a pyridine skeleton substituted by two amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID16352Dissociation constant (pKa)1980Journal of medicinal chemistry, Apr, Volume: 23, Issue:4
2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 3. C-Benzylation of aminopyridines with phenolic Mannich bases. Synthesis of 1- and 3-deaza analogues of trimethoprim.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (50.00)18.7374
1990's2 (10.00)18.2507
2000's5 (25.00)29.6817
2010's3 (15.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.47 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]